Facial redness in Japanese adolescents with atopic dermatitis treated with dupilumab: A case series

Shuhei Hara; Takaaki Itonaga; Makoto Nishino; Noriyuki Yanagida; Sakura Sato; Motohiro Ebisawa

doi:10.1016/j.jacig.2023.100096

Facial redness in Japanese adolescents with atopic dermatitis treated with dupilumab: A case series

J Allergy Clin Immunol Glob. 2023 Mar 21;2(2):100096. doi: 10.1016/j.jacig.2023.100096. eCollection 2023 May.

Authors

Shuhei Hara¹, Takaaki Itonaga¹, Makoto Nishino², Noriyuki Yanagida^{1

2}, Sakura Sato^{1

2}, Motohiro Ebisawa^{1

2}

Affiliations

¹ Department of Pediatrics and, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
² Department of Allergy, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.

Abstract

This case series study is the first report of Japanese adolescents who experienced dupilumab facial redness after starting dupilumab treatment for refractory atopic dermatitis. In every case, dupilumab facial redness subsided without discontinuation of dupilumab within 3 months after onset.

Keywords: Atopic dermatitis; Japanese adolescent; dupilumab; erythema.

Publication types

Case Reports